Cftr Trikafta denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Imposes Quantity Limits on Trikafta

Quantity-limit (QL) denials occur when the amount of medication requested—whether measured in tablets per fill, fills per dispensing period, or total supply—exceeds the limit Aetna's pharmacy benefit manager has encoded for this drug. For a medication taken on a fixed daily schedule, quantity limits that do not align with the FDA-approved dosing regimen can interrupt therapy entirely.

This type of denial is often the result of an administrative mismatch rather than a clinical judgment: the dispensing pharmacy requested a 90-day supply while the plan's default QL is 30 days, or a dose-titration period created a quantity that looks unusual to the system. A quantity-limit exception appeal is one of the more administratively straightforward appeal categories.

## Your Federal Appeal Rights

• Quantity-limit exception request: Submit this simultaneously with the internal appeal. The prescriber must document why the requested quantity is medically necessary and consistent with the FDA-approved regimen.
• Internal appeal: File within the deadline on the denial notice. The plan must respond to pre-service appeals within 30 days (standard) or 72 hours (expedited).
• External review (ACA §2719 / ERISA §503): If the internal exception is denied, independent external review is available within approximately 4 months of the final denial. External reviewers evaluate whether the plan's quantity limit is consistent with the FDA-approved dosing regimen and accepted clinical practice.
• Expedited track: Available if any treatment gap would seriously jeopardize health.

## Documentation to Gather

1. FDA-approved prescribing label: Identify the approved dosing schedule. Confirm that the requested quantity per dispensing period matches what the label directs for a patient of this weight category, age, and clinical profile. 2. Prescriber quantity-exception letter: The letter should state the number of units requested, confirm alignment with the FDA label, and explain why any deviation (e.g., titration supply) is medically necessary. 3. Dispensing pharmacy records: Prior fill history showing consistent, appropriate use with no evidence of diversion or misuse—preempting any QL rationale based on utilization concerns. 4. Aetna quantity-limit policy: Request the current QL schedule for this drug. Identify whether the limit is below the FDA-approved supply for a standard dispensing period, and document that discrepancy.

## Criteria-Mapping Structure

| Quantity Limit Issue | Evidence | |---|---| | Requested quantity matches FDA-approved regimen | FDA label dosing schedule | | Medical necessity of requested supply duration | Prescriber letter | | No pattern of excess utilization | Pharmacy fill history | | Plan QL is below FDA-approved supply | Policy document + label comparison |

If the plan's quantity limit is facially inconsistent with the FDA-approved regimen—meaning the drug cannot be taken as directed within the allowed quantity—document that explicitly and make it the centerpiece of both the internal and external appeal arguments.